GWPH - GW Pharmaceuticals plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
136.06
+2.13 (+1.59%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close133.93
Open133.19
Bid135.05 x 800
Ask135.70 x 1300
Day's Range132.44 - 136.50
52 Week Range96.42 - 164.76
Volume238,985
Avg. Volume392,440
Market Cap3.837B
Beta2.81
PE Ratio (TTM)N/A
EPS (TTM)-9.68
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est169.00
Trade prices are not sourced from all markets
  • Party City, Roku and GW Pharma are the Yahoo Finance charts of the day.
    Yahoo Finance Video9 days ago

    Party City, Roku and GW Pharma are the Yahoo Finance charts of the day.

    Let's check out the Yahoo Finance charts of the day. Party City  (PRTY): Shares are up in early trade,  at around 4.6%.  The party goods retailer with sell products on Amazon.com in a pilot program beginning with this year's Halloween season. The company also reported adjusted quarterly profit of 40 cents per share, 1 cent a share above estimates. Roku (ROKU): Shares are up here, at around 18.50%.  The streaming video company reported a breakeven quarter, better than the 15 cents per share loss that analysts anticipated. The company also saw revenue and the number of active accounts beat Street forecasts. GW Pharma (GWPH): Shares up here, at around .77%.  The drugmaker set a price of $32,500 per year for its new epilepsy treatment, the first cannabis-based prescription drug to be approved by the Food and Drug Administration For more on today's big stock movers check out the Final Round, live at 3:55 p.m. ET, right here on Yahoo Finance.

  • 5 Marijuana Stocks With the Highest Expected Sales Next Year
    Motley Fool2 days ago

    5 Marijuana Stocks With the Highest Expected Sales Next Year

    One pot stock could approach $700 million in full-year sales.

  • Benzinga3 days ago

    Stifel Bullish On GW Pharma, Sees $1.5 Billion In Epidiolex Sales By 2023

    After a huge year in 2017, GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) stock has traded mostly sideways so far in 2018. According to Matteis, Epidiolex is such a potential money maker that GW’s story will come down to execution and access. Matteis expects a strong launch for Epidiolex, he predicted an 80 percent chance of success for the drug in Tuberous Sclerosis complex and he said extension of GW's intellectual property over time could all drive upside in the stock.

  • Investopedia6 days ago

    GW Pharma Updates on Fiscal Q3 Results & Epidiolex Progress

    GW Pharmaceuticals (NASDAQ: GWPH), a British biopharma, recently reported its third quarter earnings and progress on its cannabis-based drug for people suffering from epilepsy. The biopharma company reported an EPS of -$1.26 in fiscal Q3 compared with the Thomson Reuters’ estimate of -$2.40, while its top line touched $3.46 million in the quarter compared with Reuters’ estimates of $2 million. Apart from the financials, the highlight of the call was the update on its flagship cannabis-based epilepsy drug Epidiolex, which received U.S. FDA approval in June and will most likely hit the markets this fall.

  • This U.S. Territory Is on the Verge of Legalizing Marijuana in a Unique Way
    Motley Fool6 days ago

    This U.S. Territory Is on the Verge of Legalizing Marijuana in a Unique Way

    No U.S. state or territory has done this before.

  • This Shocking Percentage of Americans Believe Marijuana Has at Least 1 Benefit
    Motley Fool7 days ago

    This Shocking Percentage of Americans Believe Marijuana Has at Least 1 Benefit

    A new survey provides depth on the public's perception of cannabis.

  • 9 Ways to Invest in Marijuana Stocks
    Motley Fool8 days ago

    9 Ways to Invest in Marijuana Stocks

    There's more to the cannabis industry than just growers.

  • Motley Fool8 days ago

    How to Profit Off the Marijuana Industry

    There are lots of ways to invest in the growing marijuana market.

  • Party City jumps, Roku soars, GW Pharma moves higher
    Yahoo Finance9 days ago

    Party City jumps, Roku soars, GW Pharma moves higher

    Party City, Roku and GW Pharma are the Yahoo Finance shares of the day.

  • Micron, Ultra Clean Holdings, Scotts Miracle-Gro, GW Pharmaceuticals, Innovative Industrial Properties, Molson Coors and Constellation Brands highlighted as Zacks Bull and Bear of the Day
    Zacks10 days ago

    Micron, Ultra Clean Holdings, Scotts Miracle-Gro, GW Pharmaceuticals, Innovative Industrial Properties, Molson Coors and Constellation Brands highlighted as Zacks Bull and Bear of the Day

    Micron, Ultra Clean Holdings, Scotts Miracle-Gro, GW Pharmaceuticals, Innovative Industrial Properties, Molson Coors and Constellation Brands highlighted as Zacks Bull and Bear of the Day

  • The Wall Street Journal10 days ago

    New Marijuana-Based Epilepsy Treatment to Cost $32,500 a Year

    GW Pharmaceuticals PLC said it plans to charge about $32,500 per patient annually in the U.S. for its new treatment for rare forms of epilepsy, the first prescription drug derived from the marijuana plant. The U.S. Food and Drug Administration approved Epidiolex, also known as cannabidiol, in June to reduce seizures associated with forms of epilepsy known as Lennox-Gastaut syndrome and Dravet syndrome, in patients 2 years of age and older.

  • Where to Find the Best Marijuana Stocks
    Zacks10 days ago

    Where to Find the Best Marijuana Stocks

    The marijuana industry continues to grow and so do the investing opportunities. Where can you find them now?

  • Motley Fool11 days ago

    Interested in Investing in Marijuana Stocks? Here's What You Ought to Know

    The marijuana market offers investors a significant opportunity, but not every marijuana stock will be a smart investment. This is what you should know about this budding market before you invest a dime of your money.

  • InvestorPlace11 days ago

    GW Pharmaceuticals (GWPH) Stock Remains Flat as Loss Widens

    GW Pharmaceuticals NASDAQ:GWPH) stock was flat late in the day Tuesday as the company reported its latest quarterly earnings results, which saw its loss widen year-over-year, while revenue increased. For its first three quarters of fiscal 2018, the pharmaceutical company brought in cash equivalents of £334.0 million ($440.2 million), which was larger than the cash equivalents of £241.2 million that it had as of September 30, 2017. “The recent FDA approval of Epidiolex represents a major medical advance for patients with Lennox-Gastaut Syndrome and Dravet syndrome,” said Justin Gover, GW’s CEO, in relation to one of its most exciting products in the pipeline.

  • GlobeNewswire11 days ago

    GW Pharmaceuticals plc Reports Fiscal Third Quarter 2018 Financial Results and Operational Progress

    -Epidiolex ® oral solution approved by FDA and on track to be launched in Fall-- Conference call today at 4:30 p.m. ET-. LONDON and CARLSBAD, Calif., Aug. 07, 2018-- GW Pharmaceuticals plc, the world leader ...

  • Benzinga13 days ago

    CBD Poses Both Opportunities And Obstacles For The Cannabis Industry

    As California works out the kinks in its new, if long-anticipated, adult-use market and Canada prepares to roll out its nationwide industry in October, the overall cannabis industry in North America is already a multi-billion-dollar enterprise. A particularly prominent development is the diversity of hemp-based CBD products made from high-CBD, low-THC hemp. As some welcome it as a victory for medical cannabis, it may yet prove to further muddy the question of legality for CBD.

  • GW Pharma (GWPH) Q3 Earnings: Is a Turnaround in the Cards?
    Zacks13 days ago

    GW Pharma (GWPH) Q3 Earnings: Is a Turnaround in the Cards?

    GW Pharma (GWPH) is expected to report its fiscal third-quarter results next week. Investors focus is expected to be on the commercialization plan for Epidiolex.

  • The Sneaky Reason Congress May Not Want to Legalize Marijuana
    Motley Fool13 days ago

    The Sneaky Reason Congress May Not Want to Legalize Marijuana

    Hint: It's all about the money.

  • 9 Ways Marijuana Has Made History This Year
    Motley Fool13 days ago

    9 Ways Marijuana Has Made History This Year

    "Marijuana firsts" happened with regularity through the first seven months of 2018.

  • Marijuana As a Cancer Treatment? This Study Offers Early Promise
    Motley Fool14 days ago

    Marijuana As a Cancer Treatment? This Study Offers Early Promise

    Researchers may be just scratching the surface on cannabis' medical potential.

  • ACCESSWIRE16 days ago

    Cannabis Companies Set to Explode, at any Moment

    HENDERSON, NV / ACCESSWIRE / August 3, 2018 / On June 25, the FDA approved London-based GW Pharma's Epidiolex, a drug containing CBD as its active ingredient, to treat two rare and severe forms of epilepsy, ...

  • TheStreet.com18 days ago

    Insys Therapeutics Is a Pretend Cannabis Stock

    Insys continues to suck in investors who think the company is ripe for a good study result or positive nod from the U.S. Food & Drug Administration (FDA) -- and that its cheap. The latest rejection came on Friday when the FDA decided not to approve Insys' drug buprenorphine sublingual spray to treat pain as an alternative to opioids.

  • GlobeNewswire26 days ago

    Cannabinoids May Do More Than Manage Cancer Symptoms -- CFN Media

    CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article covering how cannabinoids are currently being used by physicians and how companies, such as Pascal Biosciences Inc. (PAS.V), are exploring new treatment options and combination therapies. The liberalization of cannabis laws around the world has opened the door for researchers to explore the therapeutic benefits of cannabinoids. Cannabinoids have been primarily used by physicians to treat the side-effects of cancer.

  • GlobeNewswire26 days ago

    GW Pharmaceuticals to Report Third Quarter Financial Results and Host Conference Call on 7 August, 2018

    GW Pharmaceuticals plc (GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 7 August, 2018 its third quarter financial results for the period ending 30 June, 2018. GW will also host a conference call the same day at 4:30 p.m. EDT. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

  • CarMax, J.M. Smucker, Innovative Industrial Properties and GW Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
    Zacks27 days ago

    CarMax, J.M. Smucker, Innovative Industrial Properties and GW Pharmaceuticals highlighted as Zacks Bull and Bear of the Day

    CarMax, J.M. Smucker, Innovative Industrial Properties and GW Pharmaceuticals highlighted as Zacks Bull and Bear of the Day